Merck Serono in CAR-T alliance
The cohort of companies developing products for treating cancer with genetically engineered T-cells has increased with the announcement that Merck Serono and Intrexon Corp will collaborate to generate new drug candidates using the technology.
Please sign in or register for FREE
Sign in to RegMedNet
Not yet a member? Become a member FREE to:
- Get unlimited access to ALL CONTENT
- Read selected articles from journals such as Regenerative Medicine FREE
- Receive a weekly email roundup of the latest news and expert opinions
Did you know?
Your RegMedNet account also gives you access to communities on drug discovery, real-world evidence and 3D printing in medicine. Find out more>>